Clinical Progress
Nventa originally advanced HspE7 as a single-agent therapy into multiple Phase 2 clinical trials with positive results, including trials in cervical dysplasia and recurrent respiratory papillomatosis (RRP). These trials were initiated prior to the discovery that potency could be greatly enhanced by addition of a vaccine adjuvant. Nventa is currently developing HspE7 combined with the TH1-directed adjuvant Poly-ICLC. A Phase 1b study is complete, assessing safety and tolerability in 17 patients with CIN.
Read more about this topic: Nventa Biopharmaceuticals Corporation
Famous quotes containing the word progress:
“This pond never breaks up so soon as the others in this neighborhood, on account both of its greater depth and its having no stream passing through it to melt or wear away the ice.... It indicates better than any water hereabouts the absolute progress of the season, being least affected by transient changes of temperature. A severe cold of a few days’ duration in March may very much retard the opening of the former ponds, while the temperature of Walden increases almost uninterruptedly.”
—Henry David Thoreau (1817–1862)